Arya Sciences Acquisition III in an 8-K filing said shareholders voted in favor of the SPAC’s proposed business combination with proteomics company Nautilus Biotechnology. More than 98 percent of the voted shares were cast in support of the deal. The SPAc did not disclose redemptions, if any.
Announced in February, the deal includes $150 million in Arya III’s trust account, as well as a $200 million PIPE. The combined company’s market capitalization is around $1.3 billion.
On closing, the combined company will list on the Nasdaq under NAUT. Read more.
